CMSC 2023: Multiple Sclerosis

Highlights from CMSC 2023

Aug 03, 2023

CMSC MS Conference 2023.indd

Author

Rebecca Shover

View all posts

RETURN TO Highlights from CMSC 2023

MORE FROM CMSC 2023: Multiple Sclerosis

Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS

Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS

Jun 08, 2023

Two Dietary Interventions Lead to Improvements in MS-Related Disability

Two Dietary Interventions Lead to Improvements in MS-Related Disability

Jun 07, 2023

FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS

FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS

May 24, 2023

Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings

Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings

May 24, 2023

Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis

Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis

May 24, 2023

Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment

Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment

May 24, 2023

Advertisement

RECENT ARTICLES

Brief Outpatient Rehab Program Beneficial for Post-COVID-19 Condition

Brief Outpatient Rehab Program Beneficial for Post-COVID-19 Condition

Neurological Outcomes Worsen With Gestational HTN, Preeclampsia, Eclampsia

Neurological Outcomes Worsen With Gestational HTN, Preeclampsia, Eclampsia

Prevalence of Cirrhosis Higher for Trans- Versus Cisgender Adults

Prevalence of Cirrhosis Higher for Trans- Versus Cisgender Adults

Study IDs Specific Anaphylactic Triggers Linked to Symptoms, Treatment

Study IDs Specific Anaphylactic Triggers Linked to Symptoms, Treatment

Atogepant Superior for Efficacy, Functional Measures in Migraine

Atogepant Superior for Efficacy, Functional Measures in Migraine

Prevalence of Post-COVID-19 Condition in Adults 8.4 Percent in 2023

Prevalence of Post-COVID-19 Condition in Adults 8.4 Percent in 2023

PODCAST

Preparing for Deductibles to Reset, Part 2: Centering the Patient Experience

Dec 25, 2024

Preparing for Deductibles to Reset, Part 1: Staff Training & Patient Communication

Dec 18, 2024

A Physician’s Reaction to the UnitedHealthcare CEO Shooting

Dec 11, 2024

Advertisement

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

View all newsletters

MORE FROM CMSC 2023: Multiple Sclerosis

Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS

Cortical Excitation/Inhibition Imbalance Has Predictive Value in MS

Jun 08, 2023

Two Dietary Interventions Lead to Improvements in MS-Related Disability

Two Dietary Interventions Lead to Improvements in MS-Related Disability

Jun 07, 2023

FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS

FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS

May 24, 2023

Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings

Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings

May 24, 2023

Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis

Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis

May 24, 2023

Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment

Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment

May 24, 2023

Advertisement